Trial Profile
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Subjects With Relapsed or Refractory Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary)
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms LEPUS
- Sponsors Janssen Research & Development
- 27 Feb 2024 Planned End Date changed from 31 May 2024 to 31 Mar 2024.
- 05 Dec 2023 Planned End Date changed from 31 Dec 2023 to 31 May 2024.
- 11 Aug 2022 Planned End Date changed from 30 Sep 2022 to 31 Dec 2023.